Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

L.A. McKeown

October 27, 2025

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

Presentation TCT 2014

Con: The Psychological Attraction Will Pass When the Data Emerges!

Presenter: Daniel I. Simon

September 16, 2014

Presentation TCT 2014

Pro: Within 10 Years, Most Coronary Intervention Will Use BRS!

Presenter: Stephan Achenbach

September 16, 2014

Presentation TCT 2014

TCT 612: Clinical Outcomes in Patients with Calcified Lesions Treated with Bioresorbable Vascular Scaffolds

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Vasileios Panoulas

September 16, 2014

Presentation TCT 2014

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Juan F. Granada

September 16, 2014

Presentation TCT 2014

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Ulrich Hink

September 16, 2014

Presentation TCT 2014

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Laura Mauri

September 16, 2014

Presentation TCT 2014

Imaging to Guide BRS: Nice to Have or Must Have?

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Evelyn S. Regar

September 16, 2014

Presentation TCT 2014

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Presenter: Andrew Farb, Mitchell W. Krucoff, Aaron V. Kaplan, Kenya Brothers

September 16, 2014

Presentation TCT 2014

Tips, Tricks, and Pearls to Optimize BRS Outcomes: From Lesion Preparation to Pharmacotherapy Considerations

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Jonathan M. Hill

September 16, 2014

Presentation TCT 2014

What Kind of Lesions are BRS Preferred in TODAY? TOMORROW?

Presenter: Dariusz Dudek, Pieter C. Smits, Vincent On-Hing Kwok, Azeem Latib

September 16, 2014

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

Good Long-term Results With FANTOM BVS, but More Data Needed

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Absorb BVS Matches Xience V in Chinese Patients

Con: The Psychological Attraction Will Pass When the Data Emerges!

Pro: Within 10 Years, Most Coronary Intervention Will Use BRS!

TCT 612: Clinical Outcomes in Patients with Calcified Lesions Treated with Bioresorbable Vascular Scaffolds

Status of DCB for PVD and Lessons Learned from the Recent FDA Panel

TCT 611: Multimodality Assessment 12 Months After Implantation of a Bioresorbable Scaffold for the Treatment of Culprit Lesions in Myocardial Infarction

The Emphatic Case for OPCs NOW for New DES Approval in the United States!

Imaging to Guide BRS: Nice to Have or Must Have?

Device Approval Considerations (Preclinical and Clinical) for Bioresorbable Scaffolds: Update on FDA Regulatory Guidelines

Tips, Tricks, and Pearls to Optimize BRS Outcomes: From Lesion Preparation to Pharmacotherapy Considerations

What Kind of Lesions are BRS Preferred in TODAY? TOMORROW?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content